In the H22 liver model, tumor assessment after combination therapy showed significant tumor growth inhibition and greater Treg reductions at study termination versus monotherapy or control, substantial increases in CD8+ cells after the second dose, and a rebound in FoxP3+ levels by the third dose in response to immune stimulation. This evidence concerns the gene CD8A and neoplasm.